Company: DVAX
Filing Date: 2025-04-22
Form Type: DFAN14A
Source: 0001193125-25-087436
Chunk: 0

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-22
Form: DFAN14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (Rule 14A-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 
 14a-6(e)(2))                                                       |

| ☐ | Definitive Proxy Statement |

| ☒ | Definitive Additional Materials |

| ☐ | Soliciting material Pursuant to §240.14a-12 |

Dynavax Technologies Corporation (Name of Registrant as Specified In Its Charter) DEEP TRACK BIOTECHNOLOGY MASTER FUND, LTD. DEEP TRACK CAPITAL, LP DAVID KROIN BRETT A. ERKMAN JEFFREY S. FARROW MICHAEL MULLETTE DONALD J. SANTEL (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box):

| ☒ | No fee required. |

| ☐ | Fee paid previously with preliminary materials. |

| ☐ | Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. |

Deep Track Capital, LP a Delaware limited partnership (“Deep Track”), together with the other participants named herein (collectively the “Participants”), issued the following press release and open letter to shareholders (the “Shareholder Letter,” and, together with the Press Release, the “Materials”) related to Dynavax Technologies Corporation, a Delaware corporation (the “Company”). Deep Track or its fellow Participants may disseminate the Materials or portions thereof from time to time. Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders Believes Company’s Misguided Acquisition Strategy is Destroying Value and Preventing Dynavax from Maximizing the Opportunities of Heplisav for Shareholders and Patients In Deep Track’s View, Properly Focusing on Heplisav Could Result in More than $1 Billion in Cash Generation by 2030 – More than Dynavax’s Current Enterprise Value Sees Shareholder Representation on Board as Necessary to Restore Investor Confidence in Dynavax and Prevent Strategic Blunders Urges Shareholders to Vote FOR Deep Track